tiprankstipranks
Advertisement
Advertisement

HALO Stock Latest News

Halozyme announces key executive leadership transition and reorganization
Company AnnouncementsHalozyme announces key executive leadership transition and reorganization
10d ago
8K
HALO
LifeMD partners with Halozyme subsidiary for exclusive testosterone program
PremiumThe Fly
LifeMD partners with Halozyme subsidiary for exclusive testosterone program
21d ago
HALO
LFMD
Halozyme Buy Rating Reiterated as Analyst Sees Limited Medicare Pricing Risk and Maintains $93 Price Target
PremiumRatings
Halozyme Buy Rating Reiterated as Analyst Sees Limited Medicare Pricing Risk and Maintains $93 Price Target
28d ago
HALO
Halozyme Earnings Call Highlights Royalty-Fueled Growth
PremiumCompany Announcements
Halozyme Earnings Call Highlights Royalty-Fueled Growth
2M ago
HALO
Halozyme price target lowered to $93 from $96 at Morgan Stanley
PremiumThe Fly
Halozyme price target lowered to $93 from $96 at Morgan Stanley
2M ago
HALO
Halozyme Maintained at Buy as Strong Execution and Shareholder Returns Offset Modest Price Target Trim to $93
PremiumRatingsHalozyme Maintained at Buy as Strong Execution and Shareholder Returns Offset Modest Price Target Trim to $93
2M ago
HALO
Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target
Premium
Ratings
Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target
2M ago
HALO
Halozyme reports Q1 non-GAAP EPS $1.60, consensus $1.52
Premium
The Fly
Halozyme reports Q1 non-GAAP EPS $1.60, consensus $1.52
2M ago
HALO
Halozyme still sees 2026 non-GAAP EPS $7.75 to $8.25, consensus $8.09
PremiumThe Fly
Halozyme still sees 2026 non-GAAP EPS $7.75 to $8.25, consensus $8.09
2M ago
HALO
HALO Earnings this Week: How Will it Perform?
PremiumPre-Earnings
HALO Earnings this Week: How Will it Perform?
2M ago
HALO
Halozyme Stockholders Back Board, Pay and Auditor Choices
PremiumCompany Announcements
Halozyme Stockholders Back Board, Pay and Auditor Choices
2M ago
8K
HALO
Halozyme announces global collaboration and license agreement with GSK
PremiumThe Fly
Halozyme announces global collaboration and license agreement with GSK
2M ago
GSK
HALO
Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis
PremiumThe FlyHalozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis
2M ago
HALO
ORKA
Halozyme names Darren Snellgrove as CFO
Premium
The Fly
Halozyme names Darren Snellgrove as CFO
2M ago
JNJ
HALO
Halozyme Appoints New Chief Financial Officer to Drive Growth
Premium
Company Announcements
Halozyme Appoints New Chief Financial Officer to Drive Growth
2M ago
8K
HALO
Halozyme price target raised to $95 from $90 at H.C. Wainwright
PremiumThe Fly
Halozyme price target raised to $95 from $90 at H.C. Wainwright
2M ago
HALO
Halozyme price target raised to $96 from $94 at Morgan Stanley
PremiumThe Fly
Halozyme price target raised to $96 from $94 at Morgan Stanley
3M ago
HALO
Halozyme: Underappreciated, Durable Royalty-Driven Growth Beyond 2028 Supports Buy Rating
PremiumRatings
Halozyme: Underappreciated, Durable Royalty-Driven Growth Beyond 2028 Supports Buy Rating
3M ago
HALO
Halozyme enters global global collaboration and license agreement with Vertex
PremiumThe Fly
Halozyme enters global global collaboration and license agreement with Vertex
3M ago
HALO
VRTX
Halozyme Names David Ramsay Interim Chief Financial Officer
PremiumCompany AnnouncementsHalozyme Names David Ramsay Interim Chief Financial Officer
4M ago
8K
HALO
Halozyme names David Ramsay as Interim CFO
Premium
The Fly
Halozyme names David Ramsay as Interim CFO
4M ago
HALO
Halozyme price target raised to $94 from $78 at Morgan Stanley
Premium
The Fly
Halozyme price target raised to $94 from $78 at Morgan Stanley
5M ago
HALO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >